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The disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) vary 
in their mode of action and when therapies are changed, the consequences on inflammatory 
and degenerative processes are largely unknown. 
OBJECTIVE:  
We investigated the effect of switching from other DMTs to fingolimod on cerebrospinal fluid 
(CSF) biomarkers. 
METHODS:  
43 RRMS patients were followed up after 4-12 months of fingolimod treatment. 
Concentrations of C-X-C motif chemokine 13 (CXCL13), chemokine (C-C motif) ligand 2 (CCL2), 
chitinase-3-like protein 1 (CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light 
protein (NFL), and neurogranin (NGRN) were analyzed by enzyme-linked immunosorbent 
assay (ELISA), while chitotriosidase (CHIT1) was analyzed by spectrofluorometry. 
RESULTS:  
The levels of NFL, CXCL13, and CHI3L1 decreased ( p < 0.05) after fingolimod treatment. 
Subgroup analysis revealed a reduction in NFL ( p < 0.001), CXCL13 ( p = 0.001), CHI3L1 ( 
p < 0.001), and CHIT1 ( p = 0.002) in patients previously treated with first-line therapies. In 
contrast, the levels of all analyzed biomarkers were essentially unchanged in patients 
switching from natalizumab. 
CONCLUSION:  
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We found reduced inflammatory activity (CXCL13, CHI3L1, and CHIT1) and reduced axonal 
damage (NFL) in patients switching from first-line DMTs to fingolimod. Biomarker levels in 
patients switching from natalizumab indicate similar effects on inflammatory and 
degenerative processes. The CSF biomarkers provide an additional measure of treatment 
efficacy. 
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Introduction 
Fingolimod is an inverse agonist for sphingosine-1-phosphate receptors, which reduce the 
number of circulating memory T cells and their infiltration of the central nervous system 
(CNS),1 and it may also influence regeneration of damaged CNS parenchyma.2 Fingolimod is 
mostly used as a second line disease-modifying therapy (DMT) in patients with relapsing-
remitting multiple sclerosis (RRMS). In two randomized clinical phase III trials (RCT), 
fingolimod reduced the relapse rate and lesion formation compared with placebo 
(FREEDOMS3 and FREEDOMS II4), and based on these outcomes, it was superior to interferon 
beta 1a (TRANSFORMS5).  
 Previous investigations of cerebrospinal fluid (CSF) biomarkers revealed altered 
profiles of immune cells and the proteins that reflect different aspects of the 
immunopathogenesis of multiple sclerosis (MS). We have demonstrated that natalizumab 
treatment of RRMS reduced the CSF level of the neurofilament light protein (NFL) to levels 
found in healthy controls (HC).6 Recently, fingolimod showed similar effects on axonal damage 
in a subgroup of patients participating in one of the pivotal RCTs for this treatment.3, 7 In these 
patients, the reduction of the CSF NFL level correlated with improvements in relapse and MRI 
findings.7 
In the present study, we investigated the concentration of biomarkers in the CSF from 
RRMS patients who switched to fingolimod from first line therapies (interferon beta, 
glatiramer acetate, and teriflunomide) because of breakthrough disease activity or second line 
therapy (natalizumab) to reduce the risk of progressive multifocal leukoencephalopathy (PML) 
in patients positive for the JC virus. We used biomarkers that reflect leukocyte trafficking: C-
X-C motif chemokine 13 (CXCL13), chemokine (C-C motif) ligand 2 (CCL2), also known as 
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Monocyte Chemoattractant Protein-1, MCP-1); microglial activation: chitinase-3-like protein 
1 (CHI3L1, also known as YKL-40) and chitotriosidase (also known as chitinase 1, CHIT1); axonal 
degeneration: neurofilament light protein (NFL); synaptic degeneration: neurogranin (NGRN); 
and astrocytic reaction: glial fibrillary acidic protein (GFAP).  
Except for NGRN, all of these biomarkers have previously been associated with disease 
activity8-17 or progression11, 12, 18 in MS, and DMTs have reduced the CSF levels of NFL,6, 15 
CHI3L1,19 CHIT1,20 and CXCL13.21 The major component of the cytoskeleton of the axon, NFL, 
is released into the CSF with neuroaxonal degeneration12, 14 and is increased during all stages 
of MS, with the highest levels following acute relapses12 or contrast enhancing lesions.15 The 
biomarker CHI3L1 is expressed on macrophages, epithelial cells, and astrocytes, and is 
involved in the pathogenesis of chronic autoimmune disorders.22 High CSF levels of CHI3L1 
were associated with disability progression and shorter time to conversion from clinically 
isolated syndrome to MS.11 The biomarker NGRN is a postsynaptic protein that is enriched in 
dendritic spines and elevated levels were found in subjects with mild cognitive impairment 
(MCI) and Alzheimer disease (AD).23, 24 In CSF, NGRN is a marker of synaptic integrity and its 
levels are influenced by neurodegeneration.25 A better understanding of these biomarkers and 
their response to DMTs could lead to their implementation in clinical practice and treatment 
monitoring. 
 
Material and methods 
Patients and healthy control subjects  
Patients with RRMS fulfilling the revised McDonald criteria26 were consecutively enrolled in 
the study at the MS centers of Sahlgrenska University Hospital, Gothenburg (n=17) and 
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Karolinska University Hospital, Stockholm, Sweden (n=16). In total, 43 patients were included, 
3 treatment naïve and 40 patients switching from another DMT. Treatment with oral 
fingolimod, 0.5 mg once daily, started at baseline. Patients were prospectively followed and 
had a second assessment, including lumbar puncture after 4 (n=4), 6 (n=18), 9 (n=3), or 12 
(n=18) months. According to their previous treatment, these patients were divided into first-
line (n=26, interferon beta, glatiramer acetate, and teriflunomide) and second-line treatment 
groups (n=14, natalizumab). The reasons for switching to fingolimod from first-line treatments 
were evidence of breakthrough disease (n=23), insufficient compliance (n=1), and 
undocumented (n=2). All of the second-line treated patients were serum positive for the JC 
virus antibody (JCV+) and had been on natalizumab treatment for 25 months or more and 
switched because of the increased risk for PML. The median wash-out period before starting 
fingolimod treatment was 22 days (range 0-1107; four patients had a treatment interruption 
for >1 year) for the first-line treated patients, and 81 days, (range 42-134) for second–line 
treated patients. Thirty-nine blood donors and university students served as age-matched HC. 
None of them had any neurological signs or a history of neurological disease. Demographic 
and clinical characteristics of the cohorts of patients and HC are presented in Table 1.  
 
Clinical assessments and MRI 
Patients underwent a clinical neurological examination, MRI scanning, and lumbar puncture 
at baseline and after 4-12 months of fingolimod treatment. A relapse was defined according 
to McDonald criteria as an episode of neurological disturbance lasting for at least 24 h.27 The 
neurological examinations were performed by trained neurologists and disability was 
measured using the Expanded Disability Status Scale (EDSS)28 and disease severity with the 
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Multiple Sclerosis Severity Score (MSSS).29 The MRI scans of the brain and cervical column 
were performed with 1.5 or 3.0 Tesla machines using a 3 mm slice thickness, and in close 
association with the clinical neurological examinations and lumbar puncture (median 44 days, 
range 0-379). A standard protocol for MS was applied with T1- and T2-weighted sequences, 
FLAIR, and T1 following a standard dose of intravenous gadolinium (Gd) contrast. New disease 
activity on MRI was defined as a new Gd-enhanced lesion or a new or enlarged T2 lesion. 
 
Blood tests and CSF sampling 
Peripheral blood and CSF were sampled at the clinical assessment. The CSF samples were 
handled according to the consensus protocol of the BioMS-EU network for CSF biomarker 
research in MS.30 Disease activity (relapse, contrast enhancing T1, and new or enlarged T2) 
was recorded at baseline and at follow-up (Table 2). At follow-up, none of patients had relapse 
prior to lumbar puncture.  
 
Biomarker analysis 
All analyses were performed by board-certified laboratory technicians at the Clinical 
Neurochemistry Laboratory, at the Sahlgrenska University Hospital, according to protocols 
approved by the Swedish Board for Accreditation and Conformity Assessment. The NFL 
protein was measured with a sensitive sandwich ELISA method (NF-light® ELISA kit, 
UmanDiagnostics AB, Umeå, Sweden). Intra- and inter-assay coefficients of variation were 
below 10%. The lower limit of quantification (LLoQ) of the assay was 31 pg/mL. The GFAP was 
measured by ELISA, as previously described.31 Briefly, ELISA plates were coated with hen anti-
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GFAP IgG followed by incubation with CSF samples for 2 h, then rabbit anti-GFAP IgG was 
added as a secondary antibody and incubated for 1 h, both at room temperature. Detection 
was performed with peroxidase-conjugated donkey anti-rabbit IgG and 3,3’,5,5’-
tetramethylbenzidine substrate. The absorbance was read at λ 490 nm, and the sensitivity of 
the GFAP assay was 16 pg/mL. The CXCL13 was measured by ELISA (Human CXCL13/BLC/BCA-
1 Immunoassay, R&D Systems Inc., Abingdon, United Kingdom), according to the 
manufacturer’s instructions. The average intra- and inter-assay coefficients of variation were 
≤ 10%. The LLoQ was 7.8 pg/mL and CSF samples below that level were designated the value 
7.8 pg/mL. The CHI3L1 was analyzed with solid phase sandwich ELISA (Human Chitinase 3-like 
1 Quantikine ELISA Kit, R&D Systems Inc., Minneapolis, MN). The intra-assay coefficient of 
variation was below 7% and the LLoQ was 8.15 pg/mL. The CCL2 was analyzed by solid phase 
sandwich ELISA (Human CCL2/MCP-1 Quantikine ELISA Kit, R&D Systems Inc., Minneapolis, 
MN). Intra- and inter-assay coefficients of variation were ≤ 8% and the LLoQ of the assay was 
10 pg/mL. The CSF NGRN was measured using an in-house ELISA with the monoclonal antibody 
Ng7 (BioLegend) as the capture antibody and the rabbit anti-NGRN antibody (Upstate) as the 
detecting antibody. The LLoQ was 125 pg/mL and the mean intra-assay coefficient of variation 
was 17%. The CSF chitotriosidase activities were measured with an in-house method in which 
100 µL of a fluorescence-linked substrate, 4-MU-β-D-N,N’N’’-triacetylchitotrioside (Sigma 
M5639) was added to 100 L CSF and incubated for 15 min at 37oC. In the presence of 
chitotriosidase, the β-chain cleavage leads to release of the fluorescence element into the 
samples, which is quantified by spectrofluorometry (Jasco, Cremella, Italy). A serial dilution of 
pooled reference plasma was used as a standard from which activities were calculated. The 
LLoQ was 0.2 nkat/L and intra- and inter-assay coefficients of variations were <10%.  
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Statistical analysis 
The Shapiro-Wilk test of normality did not show normal distribution of our data; therefore, 
non-parametric tests were used in this study. Wilcoxon signed ranks test were used for paired 
data and the Mann-Whitney U test for unpaired data. Correlations between biomarkers were 
analyzed with Spearman’s rank correlation test. Multiple regression analysis was performed 
to test the influence of gender, age, disease duration, EDSS, and MSSS on the biomarkers. 
Statistical calculations were performed in SPSS Statistics 21 software. 
Ethics 
All patients and HC voluntarily participated in the study and informed consent was obtained 
from all subjects after oral and written information was provided. The regional ethical review 




Biomarker concentrations after fingolimod treatment 
The patients who were followed-up after 4-12 months of fingolimod treatment (n=43) had 
significantly reduced CSF levels of NFL, CXCL13, and CHI3L1 compared with their baseline. The 
mean pre-treatment level of NFL, 1 183 pg/mL (SD 2 135), decreased to 654 pg/mL (SD 448; 
p=0.036) after treatment, the CXCL13 level decreased from 19.0 pg/mL (SD 25.9) to 8.1 pg/mL 
(SD 1.2; p=0.001), and the CHI3L1 level decreased from 144 ng/mL (SD 67) to 119 ng/mL (SD 
40; p<0.001, Fig 1-3). The mean post-treatment levels of NFL and CHI3L1 were significantly 
higher than in HC (p<0.001 for both); whereas, the mean post-treatment level of CXCL13 was 
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similar to that of HC (Figures 1-3). The mean levels of CCL2 and GFAP did not significantly 
change prior to and after the treatment with fingolimod; in fact, both baseline and follow-up 
concentrations were similar to those of HC. Although patients had lower pre- and post-
fingolimod treatment levels of NGRN (p=0.059 and p=0.020, respectively) and higher levels of 
CHIT1 (p<0.001 and p<0.001, respectively) compared with HC, fingolimod did not influence 
their mean levels. The levels of NFL, GFAP, and CCL2 were detectable in all patients and HC. 
The levels of CXCL13 were below the LLoQ in 39 HC and 27 patients, the levels of CHIT1 were 
below the LLoQ in 12 HC and 6 patients, and the levels of NGRN were below the LLoQ in 14 
HC and 20 patients. 
 
The influence of previous DMT on biomarker concentrations 
At baseline, patients previously treated with first line therapies had significantly higher levels 
of NFL (p=0.006), CXCL13 (p=0.005), CHI3L1 (p=0.025), and CHIT1 (p=0.005) compared with 
those previously treated with natalizumab, a second line therapy; whereas, their NGRN levels 
were lower (p=0.067). There was no difference in the pre-fingolimod treatment levels of GFAP 
and CCL2 between first and second line treatment groups. Fingolimod treatment decreased 
the levels of NFL, CXCL13, CHI3L1, and CHIT1 (p<0.001, p=0.001, p<0.001, and p=0.002, 
respectively) in patients who switched from first line therapies. However, the levels of these 
biomarkers were still significantly higher after fingolimod treatment compared with controls 
(p<0,001, p=0.031, p<0.001, and p<0.001, respectively). In contrast, the levels of all analyzed 
biomarkers were essentially unchanged by fingolimod treatment in patients who switched 
from natalizumab treatment (Table 2 and Fig 1-3). Only CHIT1 was significantly increased in 
patients treated with natalizumab compared with HC (p=0.032). 
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The influence of fingolimod treatment duration on biomarker concentrations  
Patients were dichotomized into those who had fingolimod treatment for less or more than 6 
months. Subgroup analysis revealed that fingolimod treatment for 6 months or less, reduced 
CSF levels of NFL (p=0.002), CXCL13 (p=0.012), and CHI3L1 (p=0.001). There were no significant 
differences between biomarker levels from patients who were followed for up to 6 months 
and those who were followed for more than 6 months (Table 3). 
 
Clinical and radiological effects of fingolimod treatment  
Prior to fingolimod treatment, patients on first line treatments had more disease activity as 
determined by both clinical and radiological measures, than those on second line treatment 
(Table 4). Within 3 months prior to switching to fingolimod, 5 patients on first line treatment 
had a relapse and 10 patients displayed ≥1 Gd-enhanced lesion; while, only one patient on 
second line treatment had ≥1 Gd-enhanced lesion with no relapse. At follow-up and while 
treated with fingolimod, no patient experienced relapses in either group and one patient in 
each group displayed ≥1 Gd-enhanced lesion. The number of new T2 and Gd-enhancing lesions 
were decreased significantly in patients previously on first line treatments (p=0.007 and 
p=0.001, respectively). In contrast, fingolimod had no significant effect on disability or disease 
severity during follow-up. The median pre-treatment EDSS was 2.5 (0-6.5) in the group 
switching from first line treatments and 3.25 (0-6.5) in the group on second line treatment. 
The median post-treatment EDSS values were 2.5 (0-6.5) and 3.0 (0-6.5), respectively. The 
median pre-treatment MSSS was 3.58 (0.17-8.15) in the group on first line treatment and 3.38 
(1.04-7.41) in the group on second line treatment and the median post-treatment MSSS values 
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were 3.00 (0.16-8.14) and 3.34 (1.04-7.14), respectively. There were no significant group 
difference regarding EDSS and MSSS at baseline and the multiple regression analysis excluded 
the influence of gender on the biomarker levels of MS patients. 
 
Correlations between clinical and radiological outcomes and biomarkers  
The decrease of the relapse rate correlated with the decrease of the CHIT3L1 level (r=0.491, 
p=0.001), decrease of Gd-enhanced and T2 lesions (r=0.401, p=0.010 and r=0.329, p=0.038, 
respectively). There was a lack of correlation between the biomarker levels and EDSS and 
MSSS. The decrease of Gd-enhanced lesions correlated with the CHIT3L1, NFL, and CXCL13 
levels (r=0.409, p=0.009; r=0.396, p=0.011; and r=0.345, p=0.029; respectively) and the 
decrease of T2 lesions correlated with the CHIT3L1, NFL, and NGRN levels (r=0.383, p=0.015; 
r=0.424, p=0.008; and r=-0.341, p=0.031; respectively).  
 
Discussion 
In the present study, we demonstrated that fingolimod treatment reduced biomarker 
concentrations in CSF, reflecting reduced microglial activation (CHI3L1, CHIT1), B-cell activity 
(CXCL13), and axonal damage (NFL) in patients with RRMS. This effect was observed in patients 
previously treated with first line therapies, and the majority of these patients switched to 
fingolimod because of breakthrough disease activity. In contrast, the biomarker levels were 
essentially stable in JCV+ patients previously treated with natalizumab. The switch to 
fingolimod in these patients was motivated entirely by being JCV+ and was a measure to 
reduce the risk of PML. In contrast to the former group, these patients were all clinically and 
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radiologically stable before the switch. Thus, based on CSF biomarker concentrations, the 
influence of fingolimod on pathological processes of RRMS seemed to be superior to first line 
therapies and equal to natalizumab.  
However, even on fingolimod treatment, CHI3L1, CHIT1, CXCL13, and NFL 
concentrations did not reach the levels observed in age-matched HC. This is in contrast to 
previous reports on natalizumab treatment of RRMS patients that showed decreased NFL and 
CXCL13 levels compared with those observed in HC.6, 21 In the present study, we confirmed 
these biomarker levels in natalizumab treated patients. Of the analyzed biomarkers, only 
CHIT1 was increased compared with HC in natalizumab treated patients prior to switching to 
fingolimod. Thus, although the biomarker levels of patients previously treated with 
natalizumab did not increase significantly compared with baseline levels and generally 
remained at low levels after fingolimod treatment, the CHI3L1, CHIT1, and NFL levels were still 
significantly higher than those of HC. Fingolimod treatment reduced the relapse rate and 
formation of new lesions on MRI. Again, this effect was entirely attributed to the group of 
patients previously on first-line drugs. The measures of decreased disease activity correlated 
with reduction of these biomarkers.  
The marker GFAP indicates MS progression, correlates with EDSS and MSSS,12, 18 and is 
believed to reflect astrogliosis.18 Our result is in line with this assumption since no clinical 
neurological deterioration was observed and the GFAP level remained essentially unchanged. 
However, in previous studies, the highest correlation was confined to patients with 
progressive MS who had a mean follow-up of 9 years.18 Thus, the selection of patients and the 
limited time of follow-up in the present study might also have influenced the results. 
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Astrocytes are the major CNS source of CCL2 in both experimental autoimmune 
encephalomyelitis and MS,10, 17 but it is also produced by endothelial cells.32 We could not 
show that fingolimod influenced the CCL2 level in CSF. In previous studies, CSF levels of CCL2 
were lower in active MS, with a median EDSS of 5.0,9, 16 but did not differ significantly in stable 
MS with a low EDSS (1.5-3.0) compared with controls.16 The temporal decrease of CCL2 is 
related to clinical relapse onset and is increased thereafter (analyzed after 5 and 15 weeks).33 
Thus, the less disabled patients and CSF sampling essentially during clinically stable periods 
probably explain why CCL2 levels were not significantly different compared with HC.  
In contrast to previous studies on MCI and AD,23-25 NGRN levels were higher in HC than 
in RRMS patients and were not influenced by the fingolimod treatment. In MCI and AD, the 
dendritic spines are degenerated and the NGRN level increases and is correlated with 
cognitive decline.25 We show for the first time that the NGRN concentration is decreased in 
RRMS; although, the reason for this reduction is unknown. However, the mean CSF NGRN level 
was not significantly different between RRMS patients previously treated with first-line 
compared with second line treatments, and fingolimod did not influence the level. Thus, the 
rate of neuroinflammation did not seem to involve degeneration of dendritic spines in RRMS.  
The treatment duration and length of wash-out periods may influence biomarker 
levels at baseline. However, the mean wash-out period was longer in the group on second line 
treatment so it cannot explain the higher levels of biomarkers found in patients on first line 
treatment at baseline. There were four patients who switched to fingolimod from first line 
treatment with treatment interruptions of more than one year. However, excluding these 
patients from the analysis did not significantly change the results.  
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Some of the biomarkers (NFL, GFAP, CHI3L1, and CCL-2) are age-dependent. In the 
subgroup analysis based on the previous treatment, the group previously treated with second 
line treatments was older than the group previously treated with first line treatments. If there 
was a positive correlation between those biomarkers and age, there would be increased levels 
in the second line treatment (natalizumab) group. However, we did not find any significant 
increase in these biomarkers. The biomarkers were not gender dependent and there was no 
relationship between the biomarker levels and EDSS or MSSS. 
In conclusion, our study confirms that CSF biomarkers reflect both disease activity and 
DMT efficacy. These findings add to those obtained from clinical and MRI measures, since the 
influence of DMT on CSF biomarkers is selective, i.e. different parts of the 
immunopathogenesis of MS are involved. Fingolimod reduced B-cell activity (CXCL13), 
markers of glial activation (CHI3L1, CHIT1), and axonal degeneration (NFL) in RRMS patients 
with breakthrough disease while on first-line DMTs; while, the levels of the analyzed 
biomarkers were essentially unchanged in patients who switched from natalizumab. The 
determination of these biomarkers in CSF may be a measure of treatment efficacy in clinical 
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Figure 1. Neurofilament light (NFL) in cerebrospinal fluid before and after 4-12 months of 
fingolimod treatment (n=43). The NFL levels were compared with levels obtained in age-
matched healthy controls (n=39). The box indicates the interquartile range (IQR), bar 
indicates the median, and whiskers indicate the 95% CI. Extreme values are marked with 
open dots (±1.5 x IQR) or with asterisks (±3 x IQR). 
Figure 2. Levels of CXCL13 in cerebrospinal fluid before and after 4-12 months of fingolimod 
treatment (n=43). The CXCL13 levels were compared with levels obtained in age-matched 
healthy controls (n=39). The box indicates the interquartile range (IQR), bar indicates the 
median, and whiskers indicate the 95% CI. Extreme values are marked with open dots (±1.5 x 
IQR) or with asterisks (±3 x IQR). 
Figure 3. Levels of CHI3L1 in cerebrospinal fluid before and after 4-12 months of fingolimod 
treatment (n=43). The CHI3L1 levels were compared with levels obtained in age-matched 
healthy controls (n=39). The box indicates the interquartile range (IQR), bar indicates the 
median, and whiskers indicate the 95% CI. Extreme values are marked with open dots (±1.5 x 












Table 1. Baseline demographic and clinical charecteristics of patients with relapsing-remitting 
multiple sclerosis and healthy controls. 
      Patients (n=43) Controls (n=39) 
Gender, Men/Women, no   16/27 25/14 
Mean age, years (range)  39,65 (19-59) 33,59 (21-56) 
Median/Mean EDSS (range)  2,5/2,63 (0-6,5) NA 
DMT, no No previous treatment 3 NA 
 First line treatment  Interferon beta 19 NA 
  Glatiramer acetat 5 NA 
  Teriflunomide 2 NA 
 Second line treatment Natalizumab 14 NA 










Biomarkers as measures of treatment efficacy 
 
Table 2. Mean concentrations of CSF biomarkers before and after treatment of fingolimod in 
relapsing-remitting multiple sclerosis  
  First line treatment (n=26) Second line treatment (n=14) HC (n=39) 
  Baseline Follow-up Baseline Follow-up   
NFL (pg/mL) 1 468 (SD 2 513)a 668 (SD 545)a,b 776 (1 466) 578 (350)a 364 (254) 
CXCL13 (pg/mL) 25.8 (31.6)a 8.3 (1.5)a,b 8.4 (2.2) 7.8 (0) 7.8 (0) 
CHI3L1(ng/mL) 160 (67)a 125 (41)a,b 111 (49) 107 (35)a 85 (31) 
GFAP (pg/mL) 571 (240) 554 (185) 553 (206) 549 (166) 465 (210) 
MCP1 (pg/mL) 398 (173) 381 (139) 406 (102) 375 (98) 375 (101) 
NGRN (pg/mL) 164 (75)a 172 (94)a 226 (111) 193 (105) 241 (155) 
CHIT1 (nkat/L) 1.95 (1.76)a 1.66 (1.58)a,b 0.81 (1.12)a 1.19 (1.45)a 0.37 (0.28) 
HC=healthy controls; NFL=neurofilament light; CXCL13=C-X-C motif ligand 13; CHI3L1=chitinase-3-like 
protein 1; GFAP=glial fibrillary acidic protein; MCP-1=monocyte chemoattractant protein-1; 
NGRN=neurogranin; CHIT1=chitotriosidase; a p<0.05 patients vs. HC; b p<0.05 before vs after 











Biomarkers as measures of treatment efficacy 
 
Table 3. Influence from fingolimod treatment duration on clinical and MRI activity in relapsing-
remitting multiple sclerosis  
Follow-up period up to 6 months  more than 6 months 
Number of Patients 22  21 
Gender F//M 13//9  14//7 
Age, mean (range) 
1st line//2nd line//n previous treatment  
40,91 (23-57) 
13//6//3 
 38,33 (19-59) 
13//8//0 
Relapse within 3m before switch, n (percent) 4 (18,2 %)  2 (9,5 %) 
Relapse within 3w before switch, n (percent) 3 (13,6 %)  1 (4,8 %) 
Valid MRI scan prior to fingolimod, n 21  20 
     Patients with Gd+ lesions, n (percent) 6 (27,3 %)  5 (23,8 %) 
     Patients with new T2 lesions, n (percent) 17 (77,3 %)  15 (71,4 %) 
Valid MRI scan after fingolimod, n 20  18 
     Patients with Gd+ lesions, n (percent) 0 (0 %)  2 (9,5 %) 
     Patients with new T2 lesions, n (percent) 7 (31,8 %)  5 (23,8 %) 
    









Biomarkers as measures of treatment efficacy 
 
Table 4. Influence from previous first line and second line treatment on clinical and MRI 
outcome prior and after fingolimod treatment of relapsing-remitting multiple sclerosis. 
  First line treatment Second line treatment 
Number of Patients 26 14 
Gender F//M 18//8 8//6 
Age, mean (range) 37,23 (19-55) 43,86 (23-59) 
EDSS prior to fingolimod mean//median 2,31//2,5 3,14//3,25 
EDSS after fingolimod mean//median 2,15//2,5 3,18//3,0 
Relapse within 3m before switch, n (percent) 5 (19,2 %) 0 
Relapse within 3w before switch, n (percent) 3 (11,5 %) 0 
Relapse after switch, n (percent) 0 0 
Valid MRI scan prior to fingolimod, n 24 14 
     Patients with Gd+ lesions, n (percent) 10 (38,5 %) 1 (7,1 %) 
     Patients with new T2 lesions, n (percent) 23 (88,5 %) 7 (50 %) 
Valid MRI scan after fingolimod, n 22 13 
     Patients with Gd+ lesions, n (percent) 1 (3,8 %) 1 (7,1 %) 
     Patients with new T2 lesions, n (percent) 8 (30,8 %) 4 (28,6 %) 
F=female, M=male, EDSS=Expanded Disability Status Scale, Gd+=gadolinium enhancing, MRI=magnetic 
resonance imaging 
 
 
 
 
 
 
 
